VIVS
MaterialsVivoSim Labs Inc
Live · NASDAQ · May 9, Close
What's Moving VIVS Today?
No stock-specific AI insight has been generated for VIVS yet. Check back soon — insights are generated from recent news analysis.
Fundamentals
Trading
VIVS News
20 articles- VivoSim Platform Predicts Gastrointestinal Toxicity (Diarrhea) in an AI Model Trained on Human Intestinal Model Results – Without Animal TestingYahoo Finance·Apr 28, 2026
- VivoSim Announces Pricing of up to a $4 Million Public OfferingYahoo Finance·Apr 1, 2026
- VivoSim Releases Antibody Drug Conjugate (ADC) Data Showing Power to Detect ADC Toxicity and Guide Design of Safer ADCsYahoo Finance·Mar 24, 2026
- VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global SalesYahoo Finance·Mar 3, 2026
- VivoSim to Debut Antibody Drug Conjugate Data, representing a major new market for NAMkind models, at Society of Toxicology Meeting in San DiegoYahoo Finance·Feb 11, 2026
- NIO Inc. Announces Profit Alert for the Fourth Quarter of 2025Yahoo Finance·Feb 5, 2026
- NIO January Deliveries Nearly Double Year On YearYahoo Finance·Feb 2, 2026
- NIO Inc. Provides January 2026 Delivery UpdateYahoo Finance·Feb 1, 2026
- Top Midday GainersYahoo Finance·Jan 30, 2026
- BC-Most Active StocksYahoo Finance·Jan 30, 2026
- Wall Street Set to Open Lower Friday as Investors React to Trump's Choice of Warsh as Fed ChairYahoo Finance·Jan 30, 2026
- VivoSim Expands Asia-Pacific Access to NAMKind™ Human-Based Toxicology Services Through New Distributor Agreement in Korea and ChinaYahoo Finance·Jan 29, 2026
- Rivian vs. NIO: Which EV Manufacturer Stock Is Worth Buying?Yahoo Finance·Jan 28, 2026
- VivoSim Labs Appoints Amar Sethi, M.D., Ph.D. as Chief Scientific OfficerYahoo Finance·Jan 6, 2026
- Did Record 2025 Deliveries and a Multi‑Brand EV Push Just Shift NIO's (NIO) Investment Narrative?Yahoo Finance·Jan 5, 2026
- The Zacks Analyst Blog NIO, XPeng and Li AutoYahoo Finance·Jan 5, 2026
- NIO, XPeng & Li Auto Report December & Fourth-Quarter Delivery ResultsYahoo Finance·Jan 2, 2026
- NIO Posts Record December and Q4 Deliveries as 2025 Volumes SurgeYahoo Finance·Jan 2, 2026
- How Investors Are Reacting To NIO (NIO) Surging November Deliveries Across Its Multi‑Brand EV LineupYahoo Finance·Dec 13, 2025
- Nio Stock Slumps After Surprise November Delivery DropYahoo Finance·Dec 1, 2025
All 20 articles loaded
Price Data
Fundamentals
Trading
About VivoSim Labs Inc
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.